Last 1,098 INR
Change Today +10.90 / 1.00%
Volume 1.7M
ARBP On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 6:05 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

aurobindo pharma ltd (ARBP) Snapshot

Open
1,095
Previous Close
1,087
Day High
1,113
Day Low
1,085
52 Week High
02/3/15 - 1,275
52 Week Low
03/11/14 - 482.90
Market Cap
320.4B
Average Volume 10 Days
1.7M
EPS TTM
40.27
Shares Outstanding
291.8M
EX-Date
02/16/15
P/E TM
27.3x
Dividend
2.00
Dividend Yield
0.48%
Current Stock Chart for AUROBINDO PHARMA LTD (ARBP)

Related News

No related news articles were found.

aurobindo pharma ltd (ARBP) Related Businessweek News

No Related Businessweek News Found

aurobindo pharma ltd (ARBP) Details

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and markets generic pharmaceuticals and active pharmaceutical ingredients in India, the United States, Europe, and internationally. The company offers generics formulations primarily in the therapeutic areas of cardiovascular system, central nervous system, antibacterials, cephalosporins, opthalmics, oral contraceptives, gastroenterologicals, NSAIDS, anti-fungal, anti-emetics, anti-virals, anti-diabetics, anti-allergic, antibiotics, anti-retrovirals, and others. The company was founded in 1986 and is headquartered in Hyderabad, India.

9,500 Employees
Last Reported Date: 08/1/14
Founded in 1986

aurobindo pharma ltd (ARBP) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 15.9M
Whole Time Director, Member of Corporate Soci...
Total Annual Compensation: 9.0M
Vice Chairman, Chairman of Corporate Social R...
Total Annual Compensation: 9.0M
Whole Time Director and Member of Shareholder...
Total Annual Compensation: 9.0M
Compensation as of Fiscal Year 2014.

aurobindo pharma ltd (ARBP) Key Developments

Aurobindo Pharma Limited Announces Resignation of Dr. C. Channa Reddy as Independent Director

Aurobindo Pharma Ltd. announced that Dr. C. Channa Reddy an Independent Director of the company vide letter dated 27th January 2015 has submitted his resignation due to personal reasons. The Board of Directors of the Company at the meeting held on 4th February 2015 has noted and taken on record the resignation of Dr.C.Channa Reddy as an Independent Director of the Company.

Aurobindo Pharma Announces Resignation of C. Channa Reddy as an Independent Director

Aurobindo Pharma announced that Dr. C. Channa Reddy an Independent Director of the company vide letter dated January 27, 2015 has submitted his resignation due to personal reasons. The Board of Directors of the company at the meeting held on February 4, 2015 has noted and taken on record the resignation of Dr. C. Channa Reddy as an Independent Director of the company.

Aurobindo Pharma Limited Approves Second Interim Dividend for the Year 2014-15; Announces Unaudited Consolidated and Standalone Financial Results for the Third Quarter and Nine Months Ended December 31, 2014

The Board of Aurobindo Pharma Limited has considered and approved second interim dividend at 200% (INR 2 per equity share of the face value of INR 1 each) in addition to the interim dividend of 150% (INR 1.5 per equity share of the face value of INR 1 each), aggregating to 350% (INR 3.5 per equity share of the face value of INR 1 each) for the year 2014-15. The company announced unaudited consolidated and standalone financial results for the third quarter and nine months ended December 31, 2014. For the quarter, on standalone basis, the company's net sales/income from operations was INR 20,743.6 million compared with INR 18,929.1 million a year ago. Profit from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items was INR 5,038.4 million compared with INR 5,326.3 million a year ago. Profit from ordinary activities before tax was INR 4,898.4 million compared with INR 5,485.2 million a year ago. Net profit was INR 3,942.7 million or INR 13.52 per diluted share compared with INR 4,181.6 million or INR 14.34 per diluted share a year ago. For the nine months, on standalone basis, the company's net sales/income from operations was INR 59,975.8 million compared with INR 50,703.1 million a year ago. Profit from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items was INR 15,674.7 million compared with INR 11,682.2 million a year ago. Profit from ordinary activities before tax was INR 15,124.8 million compared with INR 9,307.0 million a year ago. Net profit was INR 11,793.3 million or INR 40.42 per diluted share compared with INR 3,324.5 million or INR 25.43 per diluted share a year ago. For the quarter, on consolidated basis, the company's net sales/income from operations was INR 31,424.6 million compared with INR 21,355.2 million a year ago. Profit from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items was INR 5,449.1 million compared with INR 5,678.3 million a year ago. Profit from ordinary activities before tax was INR 5,387.4 million compared with INR 5,497.3 million a year ago. Net profit was INR 3,824.0 million or INR 13.17 per diluted share compared with INR 4,161.2 million or INR 14.32 per diluted share a year ago. Consolidated net operating income was INR 31,662 million against INR 21,406 million a year ago. EBIDTA before Fx was INR 6,122 million against INR 6,438 million a year ago. PBT before Fx was INR 5,589 million against INR 5,477 million a year ago. For the nine months, on consolidated basis, the company's net sales/income from operations was INR 88,992.6 million compared with INR 57,326.0 million a year ago. Profit from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items was INR 16,595.9 million compared with INR 11,653.5 million a year ago. Profit from ordinary activities before tax was INR 16,111.0 million compared with INR 8,656.1 million a year ago. Net profit was INR 11,679.0 million or INR 40.16 per diluted share compared with INR 6,674.4 million or INR 23.01 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARBP:IN 1,098.00 INR +10.90

ARBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 435.05 INR -4.45
Cipla Ltd/India 731.90 INR +14.95
Divi's Laboratories Ltd 1,773 INR +8.65
Dr Reddy's Laboratories Ltd 3,408 INR +21.25
Ranbaxy Laboratories Ltd 733.00 INR +11.10
View Industry Companies
 

Industry Analysis

ARBP

Industry Average

Valuation ARBP Industry Range
Price/Earnings 19.7x
Price/Sales 2.9x
Price/Book 7.1x
Price/Cash Flow 16.4x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUROBINDO PHARMA LTD, please visit www.aurobindo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.